CRANBURY, N.J., March 7, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced today the closing of its previously announced public offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,500,000 shares of common stock. As a result, the Company issued a total of 11,500,000 shares in the offering at a price of $5.70 per share.
